ForPatients
by Roche

Rheumatoid Arthritis

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

Trial Status	Trial Runs In	Trial Identifier
Recruiting	3 Countries	NCT07620392 2025-523579-47-00 2025 WA46440

The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.

Official Title:

An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials

Trial Summary:

The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT07620392 2025-523579-47-00 2025 WA46440
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#18 Years	No

Inclusion Criteria:

- Completed the treatment period of the parent study
- Agreement to adhere to the contraception requirements
- Continued to be evaluated at the follow-up visit of the parent study and achieved improvement in the SJC66/TJC68 relative to baseline

© 2022 F. Hoffmann-La Roche Ltd

Exclusion Criteria:

- Withdrawal of consent and/or premature discontinuation from parent study
- Any permanent discontinuation of study drug in parent study
- Use of a prohibited therapy during the parent study
- Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant participation in the trial

© 2022 F. Hoffmann-La Roche Ltd